|
|
Epzicom (Abacavir/3TC, Kivexa)
| Brand Name: |
Epzicom |
| Generic Name: |
Abacavir/Lamivudine, ABC/3TC |
| Adult Single Dose: |
One tablet containing 600 mg ABC and 300 mg 3TC (once a day) |
| Food & Liquid Restrictions: |
None |
| Drug Class: |
NRTI |
|
|
|
- An Overview of Epzicom (Abacavir/3TC, Kivexa) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
- FAQs About Epzicom (Regularly Updated)
From The Body's "Ask the Experts" Forums
- Epzicom/Kivexa (Abacavir + Lamivudine) (August 23, 2008)
To read PDF, click here
From AIDS InfoNet
- Epzicom in, Combivir Out: New U.S. Treatment Guidelines on First-Line Therapy (January 29, 2008)
From AIDSinfo
- Epzicom (Abacavir/Lamivudine, ABC/3TC) (January/February 2008)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- Epzicom (Epivir + Ziagen) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- Patient Information About Epzicom (Abacavir/3TC, Kivexa) (PDF) (September 2007)
From GlaxoSmithKline
- The Once-Daily Abacavir/Lamivudine Co-Formulation Proves Its Mettle by Being Both Safe and Effective (September 30, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Adverse Event Risk on Abacavir + Lamivudine Is Not Higher for Patients Coinfected With Hepatitis B and/or Hepatitis C (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- Fixed-Dose Pill of Abacavir/Lamivudine Taken Once a Day Is Comparable to Twice-a-Day Abacavir + Lamivudine (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Understanding Two New Once-a-Day Combinations: Truvada and Epzicom (November/December 2004)
Daniel S. Berger, M.D., reviews issues of drug concentrations, adherence and resistance.
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- New Fixed-Dose Once-a-Day Starting Regimens: Interview With Cal Cohen, M.D. (October 26, 2004)
A leading AIDS physician looks at the advantages and disadvantages of Epzicom and Truvada for those who are first starting antiretroviral treatment.
In AIDS Treatment News, from AIDS Treatment News
- Little Leap: Gilead 2-in-1 Opens Door to Impending One-Pill Triple Combo (October 2004)
Rob Camp reports on the generally underwhelming news of the launch of Truvada and Epzicom.
In TAGline, from Treatment Action Group
- FDA Approves Two Combination Pills, Epzicom and Truvada; Comment on Commercial Race to Once-a-Day Nucleosides (August 23, 2004)
The benefits of once-a-day drugs haven't been adequately weighed against their potential risks, writes AIDS advocate John James.
In AIDS Treatment News, from AIDS Treatment News
- FDA Approves Gilead, GlaxoSmithKline Fixed-Dose Combination AIDS Drugs (August 3, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Two New Fixed-Dose Combinations Approved (August 2, 2004)
From U.S. Food and Drug Administration
- Lamivudine/Abacavir Is an Effective Nucleoside Backbone in Combinations Other Than With Tenofovir (July 13, 2004)
Results suggest that the K65R mutation is behind the failure of this three-drug combination.
In The XV International AIDS Conference, from The Body PRO
|
|
